Loading company
Just reported
Q4 FY2026 results
From Cencora's results release of November 4, 2026. These are the company's first figures; its 10-Q or 10-K replaces them when filed.
Revenue
Actual
$88.35B
+5.5% y/y
+4.2% q/qGuided
—
No guide given
EPS, GAAP
Actual
$2.71
-31% q/q
Guided
—
No guide given
Operating income, GAAP
Actual
$906.8M
-19% q/q
Guided
—
No guide given
Company outlook
Full year 2027
- EPS, adjusted$19.40 – $19.75First given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Cencora is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Medical Distribution
Graded A or B and worth $2B or more: A first, then the largest.
All 11 graded companies in its industry
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher CorporationOct 21, 2026CBGraded C, now B
MCKMckesson CorporationNov 4, 2026BAGraded B, now A
CVSCVS Health CorpNov 4, 2026BAGraded B, now A
EWEdwards Lifesciences CorporationNov 4, 2026BAGraded B, now A
BIIBBiogen Inc.Oct 28, 2026BAGraded B, now A
Built from Cencora, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
